In most pharma and biotech organizations, delays in clinical trials, regulatory submissions, and overall drug development timelines are rarely surprising.
They tend to show up across different stages of the lifecycle, often in ways that feel routine. For example, during the study start-up phase, timelines slip because site documents are still under review. Later, a submission deadline shifts because teams are still aligning data across systems. Even within review cycles, a few missing inputs can push timelines out by days. None of this feels unusual. In fact, teams often plan around it.
But over time, these small delays start adding up. A few days here, a week there, and suddenly timelines are harder to predict, teams are stretched thinner, and costs begin to creep up. That’s where the real impact shows up – not just in timelines, but in overall drug development costs, and ultimately, delays in getting the drug to market, and, consequently, the impact on profitability.
Why drug development costs keep rising despite more investment
There’s no doubt that drug development has become more expensive. Studies are more complex, global and data-intensive. Regulatory expectations continue to evolve across regions. Industry research has pointed to this trend for years. But there’s another layer to this.
Even with increased investment in systems, tools, and talent, execution still feels slow and unpredictable. The issue isn’t just the complexity of drug development; it’s how work moves across clinical and regulatory workflows within that complexity.
When processes are fragmented, work doesn’t flow cleanly. Teams spend time coordinating, following up, reconciling data, and rechecking outputs. It may not stand out in a single report, but it shows up in the effort required to get things done.
And over time, that effort translates into cost.
How clinical trial delays and regulatory submission delays increase drug development costs
The cost impact of delays rarely comes from one big event. It builds gradually across the lifecycle.
In clinical trials, delays often begin during study start-up. These clinical trial delays don’t just affect timelines, they extend operational effort across sites, monitoring, and internal teams. When one dependency slows down, everything else shifts with it.
In regulatory workflows, regulatory submission delays tend to show up as rework. A submission might look complete, but inconsistencies in data or documentation surface late in the process. Teams go back, revise, review, and align again before moving forward.
Then there’s the coordination layer. Emails to check status. Trackers to monitor progress. Meetings to align teams. All necessary, but none of it directly moves the submission or the study forward.
Individually, these moments seem manageable. But across multiple studies and submissions, they start to influence how much it actually costs to run them.
Why cost-cutting and disconnected tools don’t reduce workflow delays
When timelines slip and costs rise, organizations often respond by trying to reduce spend or introduce new tools.
But these approaches don’t address the root issue.
Reducing headcount lowers costs in the short term, but the amount of coordination required doesn’t change. In many cases, fewer people end up managing the same fragmented workflows, which increases the likelihood of delays.
Adding more tools can create a different kind of problem. A new system may improve one part of the process, but if it doesn’t integrate well with others, teams spend more time moving data between systems and keeping everything aligned.
So instead of simplifying execution, it adds another layer to manage.
At the core, the problem remains the same – work doesn’t move smoothly from one step to the next.
How process automation helps reduce hidden costs across clinical and regulatory operations
To address delays, and the costs that come with, it helps to shift the focus from individual tasks to how work flows end-to-end.
This is where process automation in pharma clinical and regulatory operations starts to make a real difference.
Take Study Start-Up for example. Documents such as protocols, investigator brochures, and site agreements move through multiple rounds of review and approval. In many organizations, this still happens through emails and shared folders, where teams track versions manually and follow up to keep things moving.
When these workflows are structured and connected, documents move through defined stages with clear ownership. Everyone works off the latest version, approvals happen within the process, and delays become visible early.
That reduces the back-and-forth that typically extends timelines.
The same applies to regulatory submissions. Instead of pulling documents together at the end and reconciling them under time pressure, teams can work within a connected workflow where data, documents, and approvals stay aligned throughout.
What changes here isn’t just speed, but the effort required to get to the same outcome. Fewer delays. Less rework. Less time spent coordinating.
And over time, that directly affects the cost of execution.
How AI helps reduce clinical trial delays and regulatory rework
Once workflows are connected, the next step is understanding where delays are likely to happen. This is where AI starts to play a more practical role.
In clinical supply planning, for example, AI can flag potential delays in packaging or distribution schedules based on past shipment timelines, site demand variability, or vendor turnaround patterns. This allows teams to adjust supply plans earlier, rather than dealing with shortages or last-minute escalations during the trial.
In regulatory workflows, AI can flag inconsistencies between documents and source data before they reach the final stages of submission. That reduces the risk of last-minute rework, which often adds both time and cost.
AI can also surface bottlenecks across workflows. If a particular review stage consistently takes longer than expected, teams can see that pattern and adjust by reallocating effort or refining the process.
Over time, this contributes to efforts to reduce time to market in clinical and regulatory operations, not by compressing timelines artificially, but by removing delays that extend them.
How reducing delays improves time-to-market and profitability in pharma
A labeling update that takes longer than expected because artwork, regulatory inputs, and regional variations are being aligned manually. A clinical supply chain delay where packaging or distribution timelines shift because data isn’t synchronized across systems. A change request that triggers multiple downstream updates, but each team works in isolation, leading to repeated coordination and validation effort.
These are not uncommon situations. But each one carries a cost.
Not just in terms of time, but in extended vendor engagement, additional operational effort, and the internal bandwidth required to keep things moving. When this happens across multiple programs, the overall drug development costs start to climb—and that directly affects profitability.
Summary
If you look across the end-to-end drug development lifecycle, the impact of delays becomes clearer when you step outside individual workflows and look at how they accumulate.
When inefficiencies are reduced across clinical and regulatory workflows, the benefits show up in multiple ways. Over time, this leads to more predictable timelines and more stable execution. And that’s where the impact on profitability becomes clearer.
When work flows more consistently, costs don’t escalate in the same way. When rework reduces, effort stabilizes. When delays are prevented, timelines become more reliable.
This doesn’t come from aggressive cost-cutting. It comes from reducing the inefficiencies that quietly increase the cost of getting work done.
Most organizations don’t notice this shift immediately because the costs don’t show up in one place. They build gradually across workflows, across teams, and across stages of the lifecycle. When you start addressing these areas — by connecting workflows, improving visibility, and enabling faster decisions — you begin to see a real difference in how consistently programs move forward and how tightly costs stay under control.
If this feels familiar – whether it’s delays in clinical supplies scheduling, challenges in managing real-world evidence, or bottlenecks in the study start-up phase, alongside issues like regulatory submissions or label change management, it may be worth taking a closer look at how these processes are currently structured. Talk to us about solutions for these challenges.
